Kristina Kligys

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 362 citations

Rheumatology, Induction Therapy, Immunology +9

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 294 citations

Fortify Maintenance Trial, Rheumatology, Withdrawal Phase 3 +7

Laminin deposition in the extracellular matrix: a complex picture emerges

Kevin J. Hamill, Kristina Kligys, Susan B. Hopkinson et al. · Journal of Cell Science · 2009 · 177 citations · Full text

Cell Adhesion, Matrix Deposition, Molecular Biology +17

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Laurent Peyrin‐Biroulet, J. Casey Chapman, Jean‐Frédéric Colombel et al. · New England Journal of Medicine · 2024 · 126 citations · Full text

The Slingshot Family of Phosphatases Mediates Rac1 Regulation of Cofilin Phosphorylation, Laminin-332 Organization, and Motility Behavior of Keratinocytes

Kristina Kligys, Jessica N. Claiborne, Phillip J. DeBiase et al. · Journal of Biological Chemistry · 2007 · 92 citations · Full text